A Study of AZD4063 in PLN R14del Dilated Cardiomyopathy
ConditionDilated Cardiomyopathy
Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18-80
SponsorAstraZeneca
About this trial
The purpose of the study is to assess the safety, tolerability and the pharmacokinetics (PK) of AZD4063 after single and multiple dose administration in participants with phospholamban (PLN) R14del dilated cardiomyopathy.
Eligibility criteria
Qualifiers
Participants must be 18 to 80 years of age inclusive, at the time of Screening
Participants with pre-existing positive screening for R14 del PLN mutation
Participants with screening Left ventricular eject fraction ≤ 45% as assessed by echocardiography
Participants with New York Heart Association (NYHA) function class I-III
Disqualifiers
Participants with positive hepatitis C antibody, hepatitis B virus surface antigen or hepatitis B virus core antibody
Known to have tested positive for Human immunodeficiency virus (HIV)
Any known genetic mutation associated with hereditary electrical or structural disease
Congenital long QT syndrome
Trial design
Treatments tested in this trial
- AZD4063
Treatment groups
31 Participants
are divided into 10 treatment groups10
Treatment groupsSee each treatment group below.
Sponsors and collaborators
Source ClinicalTrials.gov